A widespread clinical trial underway in 40 hospitals across Australia offers a new blood test that could help more patients avoid unnecessary chemotherapy.
First developed at Johns Hopkins Medicine in the United States, the test can determine if patients are at low or high risk of their cancer returning after surgery by looking for circulating tumour DNA in the patient’s blood.
The blood test is now being used to advise bowel cancer patients and has already been delivering apparent benefits.
The trial of this test could revolutionise cancer care. The next step is to determine how it can be used in the clinic.
You can read more about this story on The Conversation’s website.